Atricure Stock Price, News & Analysis

AtriCure, Inc. (Nasdaq: ATRC) has received an expanded CE-Mark indication for its AtriClip® devices in Europe. The devices are now indicated for use in patients at high risk of thromboembolism for whom left atrial appendage (LAA) exclusion is warranted. This expansion is based on substantial clinical evidence demonstrating a reduction in stroke events for patients receiving an AtriClip device.

The AtriClip family of devices are designed to exclude, electrically isolate, and eliminate the LAA during cardiac surgery. With over 550,000 patients treated worldwide, AtriCure has observed significant impact on patient care. The expanded indication confirms clinical evidence that strokes can be reduced in high-risk patients. Over 85 peer-reviewed studies involving more than 11,000 patients have been published on the safety and efficacy of AtriClip devices since 2007.

AtriCure, Inc. (Nasdaq: ATRC) reported strong Q2 2024 financial results, with worldwide revenue reaching $116.3 million, a 15.2% increase year-over-year. The company generated positive cash flow of $8.1 million in Q2. U.S. revenue grew by 12.5% to $95.5 million, while international revenue surged by 29.4% to $20.7 million. Despite revenue growth, AtriCure reported a loss from operations of $7.2 million and a net loss per share of $0.17. The company updated its full-year 2024 revenue guidance to $456-$461 million, reflecting approximately 15% growth at the midpoint. AtriCure expects full-year 2024 Adjusted EBITDA of $26-$29 million and an adjusted loss per share of $0.74-$0.82.

AtriCure (Nasdaq: ATRC), a leader in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management, has announced its participation in the Canaccord Genuity 44th Annual Global Growth Conference. The company's management is set to present on Tuesday, August 13, 2024, at 10:30 am EST.

Investors and interested parties can access a live audio webcast of the presentation through the 'Investors' section of AtriCure's website at https://ir.atricure.com. This event provides an opportunity for AtriCure to showcase its innovations and growth strategies to a global audience of investors and industry professionals.

AtriCure, Inc. (Nasdaq: ATRC) has received regulatory approval from China's National Medical Products Administration (NMPA) to market and sell several models of its AtriClip® Left Atrial Appendage (LAA) Exclusion System. This innovative device is designed to exclude and electrically isolate the LAA during cardiac surgery, addressing a major source of blood clots in patients with atrial fibrillation (Afib).

The approval marks a significant milestone in AtriCure's global expansion strategy, opening up a substantial market opportunity in China. The company plans to partner with leading medical institutions and professionals in China to provide comprehensive training and support. AtriClip devices have been successfully used in over 550,000 patients worldwide, demonstrating robust clinical data on safety and efficacy.

AtriCure (Nasdaq: ATRC) will announce its second quarter 2024 financial results on July 30, 2024. The company specializes in surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. A webcast will be hosted at 4:30 p.m. Eastern Time on the same day to discuss the results. Interested individuals can register online, and both live and replay versions of the webcast will be accessible at AtriCure's investor relations site.

AtriCure, a leading innovator in surgical treatments for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, announced its participation in the 2024 Leerink Partners Healthcare Crossroads Conference.

A fireside chat with AtriCure’s management is scheduled for Wednesday, May 29, 2024, at 10:40 a.m. Central Time. The live audio webcast will be accessible via the 'Investors' section of the company’s website.

AtriCure, Inc. reported first-quarter 2024 financial results, with worldwide revenue of $108.9 million, a 16.4% increase year over year. The U.S. revenue was $90.2 million, up 15.4% from first quarter 2023. International revenue increased by 21.5% to $18.6 million. Gross profit was $81.3 million with a gross margin of 74.7%. Loss from operations was $10.9 million. Adjusted EBITDA was $2.8 million. Full-year 2024 revenue is projected to be $459 million to $466 million, with adjusted EBITDA expected to be $26 million to $29 million.

AtriCure, Inc. (ATRC) will be participating in the 2024 Bank of America Securities Healthcare Conference. The company is known for its innovative surgical treatments for atrial fibrillation, left atrial appendage management, and post-operative pain management. The management will present on May 14, 2024, at 10:15 a.m. PDT.